Neihulizumab

Drug Profile

Neihulizumab

Alternative Names: AbGn-168; AbGn-168H; Antibody-168

Latest Information Update: 20 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AbGenomics Corporation
  • Developer AbGenomics Corporation; Boehringer Ingelheim; Stanford University
  • Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; P-selectin ligand protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Psoriatic arthritis
  • Phase I/II Graft-versus-host disease
  • Phase I Type 1 diabetes mellitus
  • Discontinued Plaque psoriasis

Most Recent Events

  • 03 Nov 2017 AbGenomics plans a phase I trial for Graft-versus-host disease (steroid-refractory) in January 2018 (NCT03327857)
  • 04 Oct 2017 AbGenomics plans a phase II trial for Ulcerative colitis (NCT03298022)
  • 20 Apr 2017 AbGenomics plans a phase IIa trial for Ulcerative colitis in the third quarter of 2017 (AbGenomics pipeline, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top